(Q36576992)

15 August 2017

1 reference

title

Drug insight: Bisphosphonates for postmenopausal osteoporosis (English)

1 reference

15 August 2017

0 references

Roland D Chapurlat

1

1 reference

15 August 2017

Pierre D Delmas

series ordinal

2

1 reference

15 August 2017

publication date

1 April 2006

1 reference

Nature Clinical Practice Endocrinology and Metabolism

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

211-9; quiz following 238

1 reference

Bisphosphonates: pharmacology, mechanisms of action and clinical uses

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Removal of osteoclast bone resorption products by transcytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Oral weekly ibandronate prevents bone loss in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Efficacy and safety of ibandronate given by intravenous injection once every 3 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

7 January 2021

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

7 January 2021

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

7 January 2021

Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

7 January 2021

Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0121

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0121

1 reference

15 August 2017

1 reference